Therapeutic drugs of gout: The progress in target selection

作者
Pei Lin,Zhendong Chen,Jun Lin
出处
期刊:International Journal of Rheumatic Diseases [Wiley]
卷期号:27 (1): e15022-e15022 被引量:2
标识
DOI:10.1111/1756-185x.15022
摘要

Gout is a chronic, inflammatory, and metabolic disease caused by the deposition of monosodium urate (MSU) crystals. It presents clinically with gout flares, chronic gouty arthritis, and tophi.1 Gout attacks are often accompanied by various serious complications, such as cardiovascular disease, hypertension, type 2 diabetes, chronic kidney disease, and premature death.2 With the improvement of living standards and intake of more and more purine-containing foods, gout incidence is increasing yearly. Presently, the incidence rate is 0.58–2.89 per 1000 person-years.3 Gout has become a severe public health problem, causing great suffering and a heavy financial burden to patients. Gout is caused by purine metabolism disorder and MSU crystals deposition around joints and other tissues. As shown in Figure 1, purine nucleotides are converted to hypoxanthine by purine nucleoside phosphorylase (PNP). Subsequently, hypoxanthine is oxidized to form xanthine by xanthine oxidase (XO). Finally, xanthine is oxidized by XO to produce uric acid.4 When the level of serum uric acid (SUA) exceeds its solubility point of 6.8 mg/dL, it is defined as hyperuricemia, which can be attributed to an excessive production or insufficient excretion of uric acid.5 In the state of hyperuricemia, urate can crystalize and deposit in joints and soft tissue. SUA levels are influenced by changes in the expression and function of urate transporters in kidney and intestine, especially urate anion transporter 1 (URAT1). In addition, MSU crystal deposition activates inflammatory cells such as macrophages and neutrophils, producing pro-inflammatory factors such as tumor necrosis factor-α (TNF-α) and Interleukin-1 (IL-1). This inflammatory response further worsens the progression of gout.6 In addition to be a nidus for gout flares, the inflammatory process causes bony erosions and cartilage damage. In clinical practice, the progression of gout can be mainly divided into three stages: gout flares, chronic gouty arthritis, and tophi. For gout flares, the first-line therapies include colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and IL-1 targeting drugs.7 For chronic gouty arthritis, there are two main clinical treatment strategies: urate-lowering therapies (ULTs) and anti-inflammatory therapies.8 For tophi, surgical removal is an option but not ideal. The best way is to adequately lower the SUA level and keep it low. ULTs can lead to the reduction of tophi, furthermore, a lower SUA level leads to a faster rate of reduction.9 In conclusion, ULTs and anti-inflammatory therapies are two main strategies for gout treatment. Anti-inflammatory therapy is the treatment and possibly prophylaxis of recurrent gout flares. However, the definitive treatment of chronic gouty arthritis and crystal deposition is lowering SUA level to target (less than 6 mg/dL) with ULTs. ULTs, including PNP inhibitors, XO inhibitors, URAT1 inhibitors, and recombinant uricases, can be mainly divided into three types of action mechanism: inhibiting uric acid production, promoting uric acid excretion, and decomposing uric acid (Figure 1). PNP inhibitors (Such as ulodesine) can reduce the production of hypoxanthine, thereby reducing the production of xanthine and uric acid, which may be a new mechanism of action to develop anti-gout drugs. However, its effect on autoimmunity needs to be carefully investigated, because inhibition of PNP activity can induce apoptosis in T-cells, B-cells, and NK-cells.10 XO inhibitors (Allopurinol, febuxostat, topiroxostat, tigulixostat, and KUX-1151) can inhibit the biosynthesis of uric acid from purine and promote the excretion of uric acid in liver and intestine. Their safety and effectiveness in treating gout have been confirmed in clinical trials.11 However, it is recommended to conduct genetic testing before using allopurinol, because variant HLA-B*58:01 allele can cause allopurinol hypersensitivity syndrome (a potentially fatal allergic reaction).12 Moreover, gout patients with a history of cardiovascular disease should use febuxostat with caution, because a higher risk of cardiovascular and all-cause mortality was shown in febuxostat versus allopurinol (the CARES trial).13 However, in contrast to CARES trial, the FAST trial suggested that there was no increased risk in cardiovascular death or all-cause death with the treatment of febuxostat.14 URAT1 is a membrane transporter responsible for the majority of uric acid reabsorption, therefore, its inhibitors are a highly effective and promising class of uricosuric agents, which target improved renal urate excretion by reducing the reabsorption of urate anions.15 The currently approved URAT1 inhibitors included probenecid, sulfinpyrazone, benzbromarone, lesinurad, and dotinurad. Probenecid is an alternative to allopurinol or febuxostat in patients with normal renal function. However, it is relatively contraindicated in patients with nephrolithiasis and ineffective in patients with renal insufficiency.16 Sulfinpyrazone can act as an antiplatelet drug and cause gastrointestinal problems, therefore it should be used cautiously in patients who are with peptic ulcer disease, anticoagulated, or have bleeding problems.17 Dotinurad is a new therapeutic option for gout and hyperuricemia, and non-inferior to benzbromarone or febuxostat in reducing SUA levels.18 For stronger inhibition activity and lower toxicity, numerous URAT1 inhibitors have been developed and investigated in clinical trials, such as epaminurad (UR-1102, URC-102), ruzinurad (SHR4640), xininurad (XNW3009), AR882, and ABP-671.19 Uricase, also known as urate oxidase, catalyzes the conversion of uric acid to allantoin, which is more easily eliminated by kidney.20 Unfortunately, unlike other mammals, uricase was lost in hominoids (including humans) during evolution.21 Therefore, to reduce SUA levels, the recombinant uricases (Rasburicase, pegloticase, SEL-212, PRX-115, and WTX221) have been developed and become a highly effective treatment for refractory gout.22 Anti-inflammatory therapies, including colchicine, NSAIDs, corticosteroids, IL-1 targeting drugs, and TNF-α antagonists, are the preferred treatments for gout flares. Colchicine inhibits the formation of β-microtubulin and reduces the production of inflammatory mediators associated with gout flare. Therefore, it can effectively relieve pain and swelling although it does not reduce SUA levels.23 NSAIDs inhibit inflammatory mediators by blocking cyclooxygenase (COX), which helps to reduce fever and relieve pain of gouty arthritis.24 Clinically used NSAIDs include indomethacin, naproxen, lumiracoxib, celecoxib, and etoricoxib. Corticosteroids can control gout by inhibiting inflammatory cells and inflammatory factors. However, long-term use of corticosteroids (such as prednisolone) can lead to suprarenal hyperfunction of glandular cortex, cardiovascular disease, or osteoporosis. Therefore, corticosteroids are only considered when NSAIDs and/or colchicine are not applicable. IL-1 is a potent multifunctional cytokine that plays a key role in gout pathogenesis.25 Drugs targeting IL-1 mainly include recombinant IL-1 receptor antagonist (anakinra), neutralizing anti-IL-1β antibodies (canakinumab), and IL-1β traps (rilonacept).26 If colchicine, NSAIDs, and corticosteroids are not applicable or have poor efficacy for gout flare patients, IL-1 targeting drugs can be considered for treatment. TNF-α antagonists (such as etanercept) also demonstrate great therapeutic potential in targeting key inflammatory factors in gout, but more clinical data support is needed.27 Traditional Chinese medicine (TCM) is widely recognized as a feasible approach to prevent gout in China and other East Asian countries. TCM can decrease the severity and frequency of gout attacks with fewer adverse events.28 However, the pharmacological mechanism and theoretical basis of TCM are still unclear, hindering extensive research on its effectiveness and widescale application.29 Therefore, it is crucial to enhance research efforts, especially multicenter clinical trials, to provide a stronger basis for TCM in reducing uric acid. Although various therapies are available for gout treatment, the target of healing gout is often not achieved. Gout therapeutic drugs cause multiple adverse events, which are low but can be severe, such as allopurinol hypersensitivity syndrome, potential cardiovascular risk of febuxostat, severe liver injury of lumiracoxib, hepatotoxicity of benzbromarone, and infusion-related reaction of pegloticase. Gout treatment often requires long-term medication, drug safety requires special attention. Therefore, there is an urgent need to develop novel drugs with long-lasting efficacy, low recurrence rates, and a good safety profile for gout patients. Pei Lin wrote the manuscript; Zhendong Chen modified the manuscript; Jun Lin conceived and revised the manuscript. All authors have read and approved the final manuscript. This work was supported by the National Natural Science Foundation of China (No. 82004027). The authors declare no conflict of interest. All data generated or analyzed during this study are included in this published article.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
花鳥院夕月完成签到,获得积分10
1秒前
2秒前
2秒前
3秒前
111完成签到,获得积分10
4秒前
wwt发布了新的文献求助10
4秒前
刘金磊完成签到,获得积分10
5秒前
斯文败类的应助被阿妤采纳,获得10
5秒前
OxO完成签到,获得积分0
5秒前
音游诗人发布了新的文献求助10
6秒前
6秒前
郎吟上邪发布了新的文献求助10
6秒前
6秒前
6秒前
不会科研的泡泡关注了科研通微信公众号
7秒前
小七发布了新的文献求助10
9秒前
冲锋猛男林完成签到,获得积分10
10秒前
10秒前
10秒前
难过冷玉发布了新的文献求助10
11秒前
哈牛柚子鹿完成签到,获得积分10
11秒前
张子文完成签到,获得积分10
11秒前
无极微光的应助被xiaobao采纳,获得20
11秒前
11秒前
ding的应助被quan采纳,获得10
12秒前
Yohann发布了新的文献求助10
12秒前
12秒前
13秒前
上卿发布了新的文献求助10
14秒前
王一完成签到,获得积分10
15秒前
张子文发布了新的文献求助10
15秒前
时嗷完成签到,获得积分10
15秒前
cc完成签到,获得积分10
15秒前
16秒前
rong发布了新的文献求助10
16秒前
Mint完成签到,获得积分10
16秒前
zhaopeng发布了新的文献求助10
17秒前
在水一方的应助被小吉采纳,获得10
17秒前
小红发布了新的文献求助10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8171039
求助须知:如何正确求助?哪些是违规求助? 9563751
关于积分的说明 21772122
捐赠科研通 7762548
什么是DOI,文献DOI怎么找? 3430786
关于科研通互助平台的介绍 2554676
邀请新用户注册赠送积分活动 2475657